An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors
Interventions: DRUG: Tivantinib|DRUG: Anti-Cancer Combination Therapy
Sponsor: ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)